Women who received thrombolytic therapy for acute myocardial infarction were at greater risk for both fatal and nonfatal complications than men.
RCT (n=41,021)
Yes
Does female sex affect mortality, stroke, and nonfatal complications in patients with acute myocardial infarction treated with thrombolytic therapy compared to male sex?
Women with acute myocardial infarction treated with thrombolytic therapy experience longer delays to treatment and have higher rates of fatal and nonfatal complications compared to men.
Objective. —To compare baseline characteristics, complications, and treatment-specific outcomes of women and men with acute myocardial infarction treated with thrombolytic therapy. Design. —Randomized controlled trial. Patients and Setting. —A total of 10315 women and 30706 men with acute myocardial infarction treated in 1081 hospitals in 15 countries as part of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I). Intervention. —One of four thrombolytic regimens: (1) streptokinase with subcutaneous heparin; (2) streptokinase with intravenous heparin; (3) streptokinase plus alteplase (tissue-type plasminogen activator) with intravenous heparin; or (4) accelerated alteplase with intravenous heparin. Main Outcome Measures. —Mortality, stroke, and nonfatal complications during 30-day follow-up. Results. —Women were on average 7 years older than men and delayed 18 minutes (median) longer after symptom onset before presenting to the hospital. After adjustment for age, women more often had a history of diabetes, hypertension, and smoking than men. Time to treatment was significantly longer in women (1.2 vs 1.0 hours; P P P P P P P P Conclusion. —Women who received thrombolytic therapy for treatment of acute myocardial infarction were at greater risk for both fatal and nonfatal complications than men. ( JAMA . 1996;275:777-782)
W. Douglas Weaver (Wed,) conducted a rct in Acute myocardial infarction (n=41,021). Thrombolytic therapy vs. Men was evaluated on Mortality, stroke, and nonfatal complications during 30-day follow-up. Women who received thrombolytic therapy for acute myocardial infarction were at greater risk for both fatal and nonfatal complications than men.